U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07679919) titled 'BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies' on June 22.
Brief Summary: Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory hematologic malignancies, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory hematologic malignancies, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of...